Diabetic Medicine · 2019 · 11 citations · 23 references
MedicineNephrologySurgeryCell TherapyDiabetologyFoot SurgeryChronic Kidney DiseaseCritical Limb IschemiaDiabetes MellitusDiabetic Foot DiseaseDiabetic Kidney DiseaseRenal IschemiaAutologous Stem Cell TherapyClinical Outcome MeasurementCritical Limb Ischemia TreatmentDiabetic Foot DisordersIschemic Organ InjuryLower Limb IschemiaMatched Control GroupTranscutaneous Oxygen Monitoring
AIM: To assess the impact of autologous cell therapy on critical limb ischaemia in people with diabetes and diabetic kidney disease. METHODS: A total of 59 people with diabetes (type 1 or type 2) and critical limb ischaemia, persisting after standard revascularization, were treated with cell therapy in our foot clinic over 7 years; this group comprised 17 people with and 42 without severe diabetic kidney disease. The control group had the same inclusion criteria, but was treated conservatively and comprised 21 people with and 23 without severe diabetic kidney disease. Severe diabetic kidney disease was defined as chronic kidney disease stages 4-5 (GFR <30 ml/min/1.73 m²). Death and amputation-free survival were assessed during the 18-month follow-up; changes in transcutaneous oxygen pressure were evaluated at 6 and 12 months after cell therapy. RESULTS: Transcutaneous oxygen pressure increased significantly in both groups receiving cell therapy compared to baseline (both P<0.01); no significant change in either of the control groups was observed. The cell therapy severe diabetic kidney disease group had a significantly longer amputation-free survival time compared to the severe diabetic kidney disease control group (hazard ratio 0.36, 95% CI 0.14-0.91; P=0.042); there was no difference in the non-severe diabetic kidney disease groups. The severe diabetic kidney disease control group had a tendency to have higher mortality (hazard ratio 2.82, 95% CI 0.81-9.80; P=0.062) than the non-severe diabetic kidney disease control group, but there was no difference between the severe diabetic kidney disease and non-severe diabetic kidney disease cell therapy groups. CONCLUSIONS: The present study shows that autologous cell therapy in people with severe diabetic kidney disease significantly improved critical limb ischaemia and lengthened amputation-free survival in comparison with conservative treatment; however, the treatment did not influence overall survival.
23
Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II)
Lars Norgren, William R. Hiatt, John Dormandy et al. · Journal of Vascular Surgery · 2007 · 8.2K citations · Full text
Medicine, Cardiology, Surgery +15
Peripheral Arterial Disease in Diabetic and Nondiabetic Patients
Edward B. Jude, Samson O Oyibo, Nicholas Chalmers et al. · Diabetes Care · 2001 · 794 citations · Full text
Medicine, Internal Medicine, Surgery +13